Author

Verónica Rodilla

Josep Carreras Leukaemia Research InstituteORCID 0000-0003-0512-4179Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Assay:scRNA-seq· 2 Approach:statistical model· 2 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Eva María Galán‐MoyaiD· 2 shared Eva MusuléniD· 2 shared Rosa Angélica Barbella-AponteiD· 2 shared Anabel Martínez-RomeroiD· 1 shared Ane Martinez‐LarrinagaiD· 1 shared Anna Martínez‐CardúsiD· 1 shared Arkaitz CarracedoiD· 1 shared Cristina GuardiaiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Eva María Galán‐MoyaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJul 30, 2026

A pan-cancer single-cell atlas of pericytes

Ane Martinez‐Larrinaga, Sandra Camargo, Marta Saraiva…·Mariona Graupera

The paper constructs a pan-cancer single-cell RNA sequencing atlas of pericytes, revealing a common transcriptional program in tumour-associated pericytes and their specialised subtypes across multiple cancers.

DOI 10.64898/2026.07.29.741412

humanscRNA-seq

𝕏 PostBluesky

Cancer BiologyCancer ResearchPeer-reviewedFeb 11, 2026

Discovery and evaluation of novel biomarkers reveal dasatinib as a potential treatment for a specific subtype of Triple-Negative Breast Cancer

Daniel Ortega-Álvarez, David Tébar-García, Marta Casado-Peláez…·Verónica Rodilla

This study identifies BC-markers in TNBC, links them to poor prognosis and dasatinib sensitivity, suggesting TAGLN as a predictive biomarker for targeted therapy.

5 citationstop 2%

humanscRNA-seq

𝕏 PostBluesky